{"id":101010,"date":"2026-10-22T10:31:45","date_gmt":"2026-10-22T14:31:45","guid":{"rendered":"https:\/\/overcentral.com\/en\/?p=101010"},"modified":"2026-10-22T10:31:45","modified_gmt":"2026-10-22T14:31:45","slug":"ftc-pricing-enforcement-101010","status":"publish","type":"post","link":"https:\/\/overcentral.com\/en\/ftc-pricing-enforcement-101010\/","title":{"rendered":"FTC warns 24 health systems over deceptive pricing practices"},"content":{"rendered":"

The Federal Trade Commission has sent an unmistakable signal to the nation’s largest hospital networks: compliance with existing healthcare pricing rules is no longer enough. On October 5, 2026, FTC Chairman issued warning letters to 24 of the country’s biggest health care organizations, making clear that the agency is prepared to deploy its full authority under<\/a> Section 5 of the FTC Act against what it views as deceptive, unfair, and anticompetitive pricing practices. The letters, accompanied by a published anonymized template, mark an escalation in the FTC’s oversight of hospital pricing transparency that reaches well beyond the Centers for Medicare and Medicaid Services (CMS) requirements already in place.<\/p>\n

The FTC’s Warning Letters: What the Agency Told 24 Major Health Systems<\/h2>\n

The warning letters delivered to 24 leading healthcare organizations carried two central messages that should command the attention of every hospital system in the United States. First, the FTC is now closely scrutinizing how healthcare organizations handle price transparency, with a particular focus on non-emergency services that are scheduled in advance. Second, and perhaps more consequentially, compliance with CMS price transparency rules does not provide a safe harbor from liability under Section 5 of the Federal Trade Commission Act. Meeting the CMS regulatory floor, in other words, does not automatically satisfy the broader consumer protection standards the FTC enforces.<\/p>\n

The FTC’s letter explicitly warned that even where pricing terms are disclosed to patients, those disclosures may still be deemed deceptive if they are incomplete. The agency specifically called out omissions such as physician fees or facility fees that are not included in upfront estimates, leaving patients with an incomplete picture of what they will actually owe. Patients who receive pricing information that omits these charges cannot meaningfully compare costs across providers, and the FTC views this as both deceptive and potentially unfair under Section 5.<\/p>\n

The letters target organizations that represent the largest and most influential segment of the American healthcare delivery system. By issuing warnings simultaneously to two dozen major systems, the FTC has effectively placed the entire hospital industry on notice that pricing transparency enforcement is a priority and that the agency is prepared to act against practices it considers misleading, regardless of whether those practices comply with CMS technical requirements.<\/p>\n

Section 5 of the FTC Act: The Legal Foundation for Healthcare Pricing Enforcement<\/h2>\n

The FTC’s authority to police deceptive, unfair, and anticompetitive business practices derives from Section 5 of the FTC Act, a statute that grants the agency broad discretion to challenge conduct that harms consumers or competition. In the warning letters, the FTC explicitly invoked this authority in the healthcare context, asserting that the price of healthcare services is a material term under the Act. This means that how hospitals present pricing information to patients is not merely a matter of regulatory compliance with CMS rules, but a core consumer protection issue subject to FTC enforcement.<\/p>\n

Section 5 prohibits both unfair methods of competition and unfair or deceptive acts or practices affecting commerce. The FTC’s letter emphasizes that incomplete or inaccurate pricing can constitute an unfair practice where it causes or is likely to cause substantial injury to consumers, particularly when patients are unable to compare pricing between providers and make informed decisions about their care. This framing is significant because it connects pricing transparency directly to patient welfare and market function, giving the FTC a powerful legal basis for enforcement actions that go beyond what CMS rules require.<\/p>\n

The agency’s position that CMS rules establish only a “regulatory floor” is a critical legal point. Healthcare organizations that have invested significant resources in achieving compliance with the Hospital Price Transparency Rule that took effect in 2021 may believe they have satisfied their obligations. The FTC’s letters make clear that this assumption is unwarranted. The agency will independently evaluate whether pricing disclosures are clear, conspicuous, complete, and not misleading, applying its own standards under Section 5 rather than deferring to CMS determinations.<\/p>\n

The Relationship Between FTC Enforcement and CMS Price Transparency Rules<\/h3>\n

The CMS Hospital Price Transparency Rule, which took effect on January 1, 2021, requires hospitals to establish, update, and make public a list of standard charges for all items and services, including in a consumer-friendly format. The rule represented a major step toward giving patients access to pricing information that had historically been difficult to obtain. CMS has enforced the rule through civil monetary penalties, and the agency has issued penalties against hospitals that failed to comply.<\/p>\n

The FTC’s warning letters acknowledge the CMS rules and the progress they represent, but the agency takes the position that CMS enforcement and FTC enforcement serve different purposes and operate under different legal standards. CMS rules focus on the disclosure of specific data elements in specific formats. The FTC Act focuses on whether consumer-facing communications are deceptive or unfair, regardless of whether they technically satisfy regulatory requirements.<\/p>\n

This distinction matters practically for healthcare organizations. A hospital could publish a machine-readable file of standard charges that satisfies every technical requirement of the CMS rule, yet still face FTC liability if the pricing information it provides directly to patients in advance of scheduled services is incomplete, misleading, or presented in a way that obscures material terms. The FTC letter specifically identifies “good faith estimates” for scheduled non-emergency services as an area of focus, noting that these estimates must include all anticipated charges to avoid being deceptive.<\/p>\n

What Constitutes Deceptive Pricing in Healthcare: Physician Fees, Facility Fees, and Incomplete Estimates<\/h2>\n

The FTC’s warning letter provides specific guidance on what the agency considers problematic pricing practices. The letter states that pricing disclosures may be deceptive if they omit certain charges, explicitly naming physician fees and facility fees as examples of costs that must be included in estimates to avoid misleading patients. This is a particularly important clarification because many hospital pricing tools and estimates separate hospital charges from physician professional fees, sometimes directing patients to consult separately with their physicians about coverage and costs.<\/p>\n

The practice of splitting pricing information across multiple communications or disclosures, even if each individual disclosure is technically accurate, can violate Section 5 if the overall impression conveyed to patients is misleading. The FTC’s letter suggests that hospitals must take responsibility for ensuring that patients receive a complete picture of anticipated costs, including all professional fees, facility fees, anesthesia charges, and other components of the total price for scheduled services.<\/p>\n

Incomplete pricing also raises concerns under the “unfairness” prong of Section 5. The FTC letter explains that where patients are unable to compare pricing between providers and make informed decisions because of incomplete or inaccurate pricing, substantial injury to consumers may occur. This injury can take the form of unexpected financial burdens, inability to choose lower-cost options, and erosion of trust in the healthcare system.<\/p>\n

The No Surprises Act, which took effect in 2022, already provides significant protections against surprise medical bills for emergency services and certain non-emergency services at in-network facilities. The FTC’s warning letters acknowledge the regulations and processes established by CMS under the No Surprises Act, but the agency makes clear that these protections do not displace the FTC’s independent authority to challenge pricing practices that are deceptive or unfair. A healthcare organization could comply fully with the No Surprises Act and the CMS price transparency rule yet still face FTC enforcement if its pricing communications to patients are incomplete or misleading in ways the agency considers material.<\/p>\n

The Healthcare Task Force and the FTC’s Enforcement Trajectory<\/h2>\n

The FTC’s warning letters reference the establishment of a Healthcare Task Force<\/a> earlier in 2026<\/a>, signaling that the agency has dedicated resources specifically to healthcare market oversight. The creation of this task force represents an institutional commitment to sustained scrutiny of healthcare business practices, including pricing, consolidation, and competitive conduct. The task force is positioned to coordinate enforcement activities across the FTC’s consumer protection and competition missions, allowing the agency to pursue cases that involve both deceptive pricing and anticompetitive market behavior.<\/p>\n

Based on the FTC’s past enforcement activities in healthcare and other industries, the coordinated issuance of warning letters to 24 major systems is unlikely to be the end of the matter. The FTC has a well-established pattern of using warning letters as a precursor to more targeted investigations, civil investigative demands, and ultimately enforcement actions against organizations that do not address the issues identified. Healthcare organizations that receive these letters, and those that operate similar pricing practices, should expect the FTC to follow up with additional information requests and scrutiny.<\/p>\n

The timing of the letters, issued in October 2026, also reflects the FTC’s broader interest in healthcare market dynamics. Consolidation among hospitals and health systems has continued, and the agency has expressed concern that larger systems may have both the incentive and the ability to engage in pricing practices that disadvantage patients and competitors. The pricing transparency enforcement initiative complements the FTC’s competition enforcement in healthcare, including challenges to mergers and anticompetitive contracting practices.<\/p>\n

Practical Implications for Healthcare Organizations: Auditing Pricing Practices and Reducing Risk<\/h2>\n

For healthcare organizations across the country, the FTC’s warning letters create an urgent imperative to conduct comprehensive reviews of pricing practices. The FTC letter itself encourages all healthcare organizations to “conduct a comprehensive review of” their pricing practices to ensure that patients and the public are provided with timely, accurate, and complete pricing for services, particularly those that can be scheduled in advance. This language signals that the agency expects proactive compliance efforts, not merely reactive responses to enforcement actions.<\/p>\n

Organizations should begin by auditing the pricing information they provide to patients for scheduled non-emergency services, including the good faith estimates required by the No Surprises Act and any additional pricing tools or cost estimators offered on hospital websites or through patient portals. The audit should assess whether these disclosures include all anticipated charges, including physician fees, facility fees, anesthesia costs, and any other components of the total price that a patient would reasonably expect to see.<\/p>\n

A critical area of focus should be the completeness of pricing disclosures. Even if a hospital’s pricing tool accurately reflects the hospital’s own charges, it may still be deceptive if it omits professional fees that patients will separately owe to physicians, anesthesiologists, radiologists, or other providers involved in their care. The FTC’s letter explicitly warns against this type of omission, and organizations should evaluate whether their pricing communications create a misleading impression of total patient cost.<\/p>\n

Healthcare organizations should also review their processes for updating pricing information. The FTC’s emphasis on “timely, accurate, and complete” pricing means that outdated or stale pricing data could form the basis for enforcement action, particularly if patients rely on that information when making decisions about where to receive care. Organizations should implement mechanisms to ensure that pricing information is reviewed and updated on a regular schedule.<\/p>\n

Preparing for Enhanced FTC Scrutiny: Compliance Programs and Documentation<\/h3>\n

Beyond auditing current pricing practices, healthcare organizations should consider strengthening their compliance programs to address FTC expectations specifically. Organizations that have focused their price transparency compliance efforts primarily on CMS requirements may need to expand their programs to incorporate Section 5 analysis. This includes training staff who prepare pricing disclosures, reviewing marketing and patient communication materials for potential deception, and establishing processes for evaluating whether pricing information is clear and conspicuous.<\/p>\n

Documentation will be important if the FTC initiates investigations. Organizations should maintain records of their pricing practices, the basis for the estimates they provide, the steps they take to ensure completeness and accuracy, and any patient complaints related to pricing and billing. Such documentation can help demonstrate good faith efforts to comply with legal obligations and may inform discussions with FTC staff if concerns arise.<\/p>\n

The FTC’s warning letters also highlight the importance of coordination between legal, compliance, finance, and clinical operations teams within healthcare organizations. Pricing transparency touches on multiple functions, and ensuring that patients receive complete and accurate pricing information requires input from revenue cycle management, health information management, and clinical departments that can identify all of the services and providers that will be involved in a patient’s care.<\/p>\n

The Broader Implications: Patient Choice, Market Competition, and the Future of Healthcare Pricing<\/h2>\n

The FTC’s enforcement initiative reflects a broader policy consensus that price transparency is essential to a well-functioning healthcare market. When patients cannot obtain reliable, complete pricing information before receiving care, they cannot shop for services based on price, and providers have reduced incentives to offer competitive pricing. The FTC’s letters send a message that the agency will not tolerate pricing practices that undermine consumer choice and market competition, even if those practices are technically compliant with other regulatory regimes.<\/p>\n

The impact on patients could be significant. If the FTC’s efforts lead to more complete and accurate pricing disclosures, patients may be better able to anticipate their financial obligations, compare costs across providers, and make informed decisions about where to receive care. This is particularly important for patients with high-deductible health plans and those who are responsible for a larger share of their healthcare costs. Complete pricing information can help patients avoid surprise bills, plan for healthcare expenses, and identify more affordable options for scheduled services.<\/p>\n

For healthcare organizations, the FTC’s increased focus on pricing transparency creates both risks and opportunities. Organizations that proactively improve their pricing practices and ensure that patients receive complete, accurate, and timely information may be able to build trust with patients and differentiate themselves in competitive markets. Organizations that resist or delay may face enforcement actions that carry significant financial and reputational consequences.<\/p>\n

The FTC’s warning letters to 24 major health systems represent a pivotal moment in the evolution of healthcare pricing regulation. The agency has made clear that it views pricing transparency as a consumer protection issue of the highest priority, and that it will use its full authority under Section 5 of the FTC Act to hold healthcare organizations accountable for deceptive, unfair, and anticompetitive pricing practices. Healthcare organizations that take the warning seriously and conduct thorough reviews of their pricing practices will be best positioned to navigate this new enforcement environment. Those that do not may find themselves answering not just to CMS, but to the FTC as well.<\/p>\n","protected":false},"excerpt":{"rendered":"

The Federal Trade Commission has sent an unmistakable signal to the nation’s largest hospital networks: compliance with existing healthcare pricing rules is no longer enough. On October 5, 2026, FTC Chairman issued warning letters to 24 of the country’s biggest health care organizations, making clear that the agency is prepared to deploy its full authority […]<\/p>\n","protected":false},"author":7,"featured_media":101012,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/cards.overcentral.com\/cards\/en\/101010.png","fifu_image_alt":"FTC warns 24 health systems over deceptive pricing practices","footnotes":""},"categories":[40657],"tags":[],"class_list":["post-101010","post","type-post","status-publish","format-standard","has-post-thumbnail","category-legal"],"fifu_image_url":"https:\/\/cards.overcentral.com\/cards\/en\/101010.png","fifu_image_alt":"FTC warns 24 health systems over deceptive pricing practices","_links":{"self":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts\/101010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/comments?post=101010"}],"version-history":[{"count":1,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts\/101010\/revisions"}],"predecessor-version":[{"id":101011,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts\/101010\/revisions\/101011"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/media\/101012"}],"wp:attachment":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/media?parent=101010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/categories?post=101010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/tags?post=101010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}